期刊文献+

紫杉醇脂质体在大鼠和荷瘤裸鼠体内的组织分布 被引量:4

Tissue Distribution of Paclitaxel Liposome in Rats and Tumor Bearing Nude Mice
下载PDF
导出
摘要 目的:运用LC-MS/MS法测定紫杉醇脂质体在大鼠和荷瘤裸鼠体内的组织分布,比较注射用紫杉醇脂质体和紫杉醇注射液的体内分布特征。方法:大鼠分组后分别iv.7 mg·kg-1受试和参比试剂,于给药前、给药后10 min、1 h、4 h采集组织样品;荷瘤裸鼠分组后分别iv.10mg·kg-1受试和参比试剂,于给药前、给药后10 min,1 h,4 h,8 h采集组织样品,利用LC-MS/MS法对组织样品中药物含量进行测定。结果:大鼠iv.紫杉醇脂质体后10 min在肝、心、肾、脑、子宫分布达到最大值,4 h后各组织中药物含量均下降;荷瘤裸鼠iv.给药后10 min在血、肝、脾、肺、肾、脂肪、睾丸分布量最大,8 h后在脾、肠、肝、肿瘤中药物含量依然较高。结论:紫杉醇脂质体和紫杉醇注射液在大鼠和裸鼠体内的组织分布一致。静脉注射紫杉醇脂质体后,均能特异地分布到肝脏、肺和肠等。两制剂比较,紫杉醇脂质体具有更好的靶向性和更高的安全性。 Objective: To analyze the tissue distribution of paclitaxel liposome in rats and tumor bearing nude mice using LC-MS/MS techniques. The characteristics of tissue distribution of paclitaxel liposome were evaluated comparing with the paclitaxel injection. Methods: Test and reference preparations were administrated at the same dose of 7 mg·kg-1 for rats, as well as 10 mg·kg-1 for tumor bearing nude mice via i.v.. Tissue samples were collected before and after the i.v. injection at different times (i.e., rats: 10 min, 1 h and 4 h; tumor bearing mice: 10 min, 1 h, 4 h and 8 h) for the determination of paclitaxel by LC-MS/MS. Results: At 10 min after administration, paclitaxel concentrations approached their maximum in heat, liver, kidney, brain and uterus of rats and in plasma, liver, spleen, lung, kidney, fat and testis of tumor bearing nude mice. At 4 h after injection, the concentration decreased in rat tissue samples while the concentrations stayed high in spleen, intestine, liver and tumor of tumor bearing nude mice until 8 h. Conclusion: The distributions of paclitaxel in rats and tumor bearing nude mice were consistent between the two preparations. After the injection of paclitaxel liposome in rats, paclitaxel was specifically distributed in liver, lung and intestine. Paclitaxel liposomes showed better targeting and higher safety than paclitaxel injection.
出处 《药学与临床研究》 2013年第2期129-132,共4页 Pharmaceutical and Clinical Research
关键词 紫杉醇 脂质体 LC-MS MS 组织分布 Paclitaxel Liposome LC-MS/MS Tissue distribution
  • 相关文献

参考文献2

二级参考文献19

  • 1Straulinger RM, Sharma A, Murray M, et al. Novel Paclitaxel formulations: taxol-containing liposomes[ J ] . J NCI Monographs, 1993,15:69. 被引量:1
  • 2Sharma A, Sharma US, Straulinger RM, et al. Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia[ J]. Cancer Lett, 1996,107:262. 被引量:1
  • 3Sharma A, Mayhew E, Bolcsak L, et al. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts [ J ]. Int J Cancer, 1997,71:103. 被引量:1
  • 4Sparreboom A,Van ZL,Brouwer E,et al.Cremophor EL-mediated alteration of paclitaxel distribution in human blood:clinical pharmacokinetic implications[J].Cancer Res,1999,59(7):1454. 被引量:1
  • 5Kloover JS,Bakker MA,Gelderblom H,et al.Fatal outcome of a hypersensitivity reaction to paclitaxel:a critical review of premedication regimens[J].Br J Cancer,2004,90(2):304. 被引量:1
  • 6Ciccolini J,Catalin J,Blachon MF,et al.Rapid high-performance liquid chromatographic determination of docetaxel(taxotere)in plasma using liquid-liquid extraction[J].J Chromatogr B,2001,759(2):299. 被引量:1
  • 7Martin N,Catalin J,Blachon MF,et al.Assay of paclitaxel(taxol)in plasma and urine by high performance liquid chromatography[J].J Chromatogr B,1998,709(2):281. 被引量:1
  • 8Wang LZ,Ho PC,Lee HS,et al.Quantitation of paclitaxel in micro-sample rat plasma by a sensitive reversed-phase HPLC assay[J].J Pharm Biomed Anal,2003,31(2):283. 被引量:1
  • 9鲁明波,梅兴国.紫杉醇的临床应用进展[J].国外医药(合成药.生化药.制剂分册),1997,18(2):94-100. 被引量:11
  • 10葛召恒,李桦,薛俊峰,王宁.高效液相色谱法测定犬血浆和小鼠组织、体液中的紫杉醇[J].药物分析杂志,1997,17(5):301-304. 被引量:11

共引文献55

同被引文献47

  • 1陈智伟,廖美琳.RECIST标准在肿瘤治疗疗效评价中的应用[J].中国肿瘤,2004,13(10):616-618. 被引量:175
  • 2仝新勇,周建平,谭燕,吴春勇,林文垚,刘馨.紫杉醇纳米脂质体在大鼠体内的药动学[J].中国医院药学杂志,2006,26(6):677-679. 被引量:10
  • 3陈宁,张琪,杜宇,陈国广,朱玲玲.黄芪甲苷在大鼠体内的药代动力学和组织分布研究[J].生物加工过程,2006,4(3):67-72. 被引量:13
  • 4钟大放.以加权最小二乘法建立生物分析标准曲线的若干问题[J].药物分析杂志,1996,16(5):343-346. 被引量:581
  • 5Li L, Liu LY, Chen M, et al. A pilot study of conformal radiothera- py combined with erlotinib - based multimodality therapy in newly diagnosed metastatic non - small - cell lung cancer[ J ]. Eur Rev Med Phamlacol Sci, 2015, 19(10) : 1812 - 1820. 被引量:1
  • 6Brown T, Pilkington G, Bagust A, et al. Corrigendum: Clinical effectiveness and cost - effectiveness of first - line chemotherapy for adult patients with locally advanced or metastatic non - small cell lung cancer: a systematic review and economic evaluation [ J]. Health Technol Assess ,2015,17(31 ) :281 -282. 被引量:1
  • 7Cheng Y.I, Lee YC, Chiu WC, et al. High Idl expression, a gener- ally negative pi~ognostic factor, paradoxically predicts a favorable prognosis for adjuvant paelitaxel plus cisplatin therapy in surgically treated lung cancer patients [ J ]. Oncotarget, 2014,5 ( 22 ) : 11564 - 11575. 被引量:1
  • 8Li Y, Wang X, Li J, et al. Combination therapy of liposomal pa- clitaxel and cisplatin as neoadjuvant chemotherapy in locally ad- vanced cervical cancer [ J ]. Eur J Gynaecol Oncol, 2015 ;36 ( 1 ) : 54 - 58. 被引量:1
  • 9Trotti A, Byhardt R, Stetz J, et al. Common Toxicity Criteria ( version 2. 0) : An improved reference for grading the acute effects of cancer treatment--Impact on radiotherapy[ J]. Int J Radiat On- col Biol Phys, 2000,47( 1 ):13 - 47. 被引量:1
  • 10Xu H, Fan M, Elhissi AM, et al. PEGylated graphene oxide for tumor - targeted delivery of paclitaxel[ J]. Nanomedicine ( Lond), 2015,10(8) :1247 - 1262. 被引量:1

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部